BridgeBio presents detailed positive results from Phase 3
- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consistently...
Stay updated with breaking news from Nasdaq Bbio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consistently...
Pinnacle Associates Ltd. reduced its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 66.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 14,750 shares of the company’s stock after selling 28,750 shares during the period. Pinnacle Associates Ltd.’s holdings in […]
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1 year […]
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) and Achilles Therapeutics (NASDAQ:ACHL – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Analyst Recommendations This is a breakdown of recent […]
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price objective lifted by BTIG Research from $32.00 to $42.00 in a research report released on Tuesday morning, FlyOnTheWall reports. Several other research firms have also commented on BBIO. Jefferies Financial Group lowered BridgeBio Pharma from a buy rating to a hold rating and upped their target […]